{"id":"rosuvastatin-plus-clopidogrel","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Muscle pain or myalgia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1771","moleculeType":"Small molecule","molecularWeight":"321.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rosuvastatin is an HMG-CoA reductase inhibitor that lowers LDL cholesterol and triglycerides while raising HDL cholesterol. Clopidogrel is a P2Y12 platelet receptor antagonist that prevents thrombotic events. The combination addresses both atherosclerotic plaque formation and thrombotic complications in cardiovascular disease.","oneSentence":"Rosuvastatin reduces cholesterol synthesis while clopidogrel inhibits platelet aggregation, together reducing cardiovascular risk through lipid lowering and antiplatelet effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:06:02.604Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Secondary prevention of cardiovascular events in patients with acute coronary syndrome or stable coronary artery disease"},{"name":"Reduction of cardiovascular mortality and morbidity in high-risk patients"}]},"trialDetails":[{"nctId":"NCT07432516","phase":"NA","title":"Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2026-02","conditions":"Coronary Artery Disease","enrollment":4400},{"nctId":"NCT07012629","phase":"PHASE3","title":"A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-11-26","conditions":"Covert Brain Infarction","enrollment":1652},{"nctId":"NCT06358313","phase":"PHASE3","title":"Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Moderate and Moderate-to-severe Stroke","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-04-10","conditions":"Ischemic Stroke","enrollment":600},{"nctId":"NCT06360120","phase":"PHASE3","title":"Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-04-10","conditions":"Ischemic Stroke","enrollment":600},{"nctId":"NCT05514938","phase":"PHASE2","title":"Polypill in Acute Coronary Syndrome","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-11-30","conditions":"Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease","enrollment":140},{"nctId":"NCT04824911","phase":"PHASE2","title":"Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-03-23","conditions":"Acute Stroke, Dual Antiplatelet Therapy, Statin","enrollment":376},{"nctId":"NCT06877390","phase":"NA","title":"Effect of Enhanced External Counterpulsation","status":"COMPLETED","sponsor":"Chongming Hospital Affiliated to Shanghai University of Health & Medicine Sciences","startDate":"2023-11-01","conditions":"Enhanced External Counterpulsation (EECP), Acute Myocardial Infarction (AMI), Drug-coated Balloon","enrollment":60},{"nctId":"NCT04847752","phase":"","title":"Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2021-03-01","conditions":"Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)","enrollment":1000},{"nctId":"NCT06112028","phase":"PHASE4","title":"Clinical Study of Tongxinluo Capsule in Preventing and Treating Restenosis After Intracranial and External Arterial Stenting","status":"NOT_YET_RECRUITING","sponsor":"Yanbin Li","startDate":"2023-10","conditions":"Stent Restenosis","enrollment":200},{"nctId":"NCT05565976","phase":"PHASE2, PHASE3","title":"Dapagliflozin Effect in Cognitive Impairment in Stroke Trial","status":"UNKNOWN","sponsor":"Jaime Daniel Mondragon","startDate":"2020-08-01","conditions":"Stroke, Ischemic, Mild Cognitive Impairment, Dementia, Vascular","enrollment":270},{"nctId":"NCT04581759","phase":"NA","title":"Endovascular Treatment and RIPC in Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2021-04-12","conditions":"Acute Ischemic Stroke, Endovascular Treatment","enrollment":300},{"nctId":"NCT04744571","phase":"NA","title":"Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Total Occlusions","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2021-02","conditions":"Coronary Artery Disease, Coronary Occlusion, Percutaneous Coronary Intervention","enrollment":200},{"nctId":"NCT03372785","phase":"","title":"The Success of Opening Concurrent CTO leSion to Improve Cardiac Function Trial in Patients With Multi-vessel Disease","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2018-04-10","conditions":"Chronic Total Occlusion of Coronary Artery, Percutaneous Coronary Intervention, Coronary Artery Disease","enrollment":240},{"nctId":"NCT04434365","phase":"PHASE1, PHASE2","title":"Effect of Berberine for Endothelial Function and Intestinal Microflora in Patients With Coronary Artery Disease","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-06-21","conditions":"Stable Coronary Artery Disease, Percutaneous Coronary Intervention","enrollment":24},{"nctId":"NCT02767401","phase":"PHASE4","title":"The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy)","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2015-09-15","conditions":"Hibernation, Myocardial, Complete Occlusion of Coronary Artery","enrollment":200},{"nctId":"NCT01241903","phase":"PHASE1","title":"Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions","status":"COMPLETED","sponsor":"Susan Smyth","startDate":"2011-06","conditions":"Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary, Hydroxymethylglutaryl-CoA Reductase Inhibitors","enrollment":54},{"nctId":"NCT02411903","phase":"PHASE4","title":"The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized and Cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction","status":"UNKNOWN","sponsor":"The Third Affiliated Hospital of Guangzhou Medical University","startDate":"2015-03","conditions":"Cerebral Infarction, Clopidogrel,Poor Metabolism of (Disorder)","enrollment":160},{"nctId":"NCT02428374","phase":"PHASE4","title":"Role of Immune Responses After Acute Myocardial Infarction","status":"UNKNOWN","sponsor":"Federal University of São Paulo","startDate":"2015-05","conditions":"Myocardial Fibrosis","enrollment":300},{"nctId":"NCT00235950","phase":"PHASE4","title":"Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-01","conditions":"Coronary Heart Disease","enrollment":255}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Crestor & Plavix"],"phase":"marketed","status":"active","brandName":"Rosuvastatin plus clopidogrel","genericName":"Rosuvastatin plus clopidogrel","companyName":"Federal University of São Paulo","companyId":"federal-university-of-s-o-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rosuvastatin reduces cholesterol synthesis while clopidogrel inhibits platelet aggregation, together reducing cardiovascular risk through lipid lowering and antiplatelet effects. Used for Secondary prevention of cardiovascular events in patients with acute coronary syndrome or stable coronary artery disease, Reduction of cardiovascular mortality and morbidity in high-risk patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}